NCT03926624 2026-01-22
Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage
Delta-Fly Pharma, Inc.
Phase 3 Terminated
Delta-Fly Pharma, Inc.
Sellas Life Sciences Group
Sunshine Lake Pharma Co., Ltd.
Astex Pharmaceuticals, Inc.
Astex Pharmaceuticals, Inc.
AbbVie
Cyclacel Pharmaceuticals, Inc.
Eisai Inc.
Seagen Inc.